Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Gas Research
Published in: Medical Gas Research 1/2013

Open Access 01-12-2013 | Review

Xenon preconditioning: molecular mechanisms and biological effects

Authors: Wenwu Liu, Ying Liu, Han Chen, Kan Liu, Hengyi Tao, Xuejun Sun

Published in: Medical Gas Research | Issue 1/2013

Login to get access

Abstract

Xenon is one of noble gases and has been recognized as an anesthetic for more than 50 years. Xenon possesses many of the characteristics of an ideal anesthetic, but it is not widely applied in clinical practice mainly because of its high cost. In recent years, numerous studies have demonstrated that xenon as an anesthetic can exert neuroprotective and cardioprotective effects in different models. Moreover, xenon has been applied in the preconditioning, and the neuroprotective and cardioprotective effects of xenon preconditioning have been investigated in a lot of studies in which some mechanisms related to these protections are proposed. In this review, we summarized these mechanisms and the biological effects of xenon preconditioning.
Literature
1.
2.
Jordan BD, Wright EL: Xenon as an anesthetic agent. AANA J. 2010, 78: 387-392.PubMed
3.
Banks P, Franks NP, Dickinson R: Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology. 2010, 112: 614-622. 10.1097/ALN.0b013e3181cea398.PubMedCrossRef
4.
Pagel PS: Cardioprotection by noble gases. J Cardiothorac Vasc Anesth. 2010, 24: 143-163. 10.1053/j.jvca.2009.03.016.PubMedCrossRef
5.
Suga K, Kawakami Y, Yamashita T, Zaki M, Matsunaga N: Characterization of 133Xe gas washout in pulmonary emphysema with dynamic 133Xe SPECT functional images. Nucl Med Commun. 2006, 27: 71-80. 10.1097/01.mnm.0000188222.07204.62.PubMedCrossRef
6.
7.
Sanders R, Franks N, Maze M: Xenon: no stranger to anaesthesia. Br J Anaesth. 2003, 91: 709-717. 10.1093/bja/aeg232.PubMedCrossRef
8.
Preckel B, Müllenheim J, Moloschavij A, Thämer V, Schlack W: Xenon administration during early reperfusion reduces infarct size after regional ischemia in the rabbit heart in vivo. Anesth Analg. 2000, 91: 1327-1332. 10.1097/00000539-200012000-00003.PubMedCrossRef
9.
Goto T, Nakata Y, Morita S: Will xenon be a stranger or a friend? the cost, benefit, and future of xenon anesthesia. Anesthesiology. 2003, 98: 1-2. 10.1097/00000542-200301000-00002.PubMedCrossRef
10.
Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR: How does xenon produce anesthesia?. Nature. 1998, 396: 324-10.1038/24525.PubMedCrossRef
11.
Yamakura T, Harris RA: Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology. 2000, 93: 1095-1101. 10.1097/00000542-200010000-00034.PubMedCrossRef
12.
Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T: The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine 3 receptors expressed in Xenopus oocytes. Anesthesiology. 2002, 96: 699-704. 10.1097/00000542-200203000-00028.PubMedCrossRef
13.
Franks JJ, Horn JL, Janicki PK, Singh G: Halothane, isoflurane, xenon, and nitrous oxide inhibit calcium ATPase pump activity in rat brain synaptic plasma membranes. Anesthesiology. 1995, 82: 108-117. 10.1097/00000542-199501000-00015.PubMedCrossRef
14.
Lopez MM, Kosk-Kosicka D: How do volatile anesthetics inhibit Ca2+-ATPases?. J Biol Chem. 1995, 270 (47): 28239-28245. 10.1074/jbc.270.47.28239.PubMedCrossRef
15.
Xu Y, Tang P: Amphiphilic sites for general anesthetic action? Evidence from 129Xe-[1H] intermolecular nuclear Overhauser effects. Biochim Biophys Acta. 1997, 1323 (1): 154-162. 10.1016/S0005-2736(96)00184-8.PubMedCrossRef
16.
Weber NC, Toma O, Wolter JI, Obal D, Müllenheim J, Preckel B, Schlack W: The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br J Pharmacol. 2005, 144: 123-132.PubMedCentralPubMedCrossRef
17.
Weber NC, Toma O, Wolter JI, Wirthle NM, Schlack W, Preckel B: Mechanisms of xenon- and isoflurane-induced preconditioning - a potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway. Br J Pharmacol. 2005, 146: 445-455. 10.1038/sj.bjp.0706324.PubMedCentralPubMedCrossRef
18.
Weber NC, Toma O, Damla H, Wolter JI, Schlack W, Preckel B: Upstream signaling of protein kinase C-epsilon in xenon-induced pharmacological preconditioning. Implication of mitochondrial adenosine triphosphate dependent potassium channels and phosphatidylinositol dependent kinase-1. Eur J Pharmacol. 2006, 539: 1-9. 10.1016/j.ejphar.2006.03.054.PubMedCrossRef
19.
Weber NC, Stursberg J, Wirthle NM, Toma O, Schlack W, Preckel B: Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo. Br J Anaesth. 2006, 97: 298-306. 10.1093/bja/ael153.PubMedCrossRef
20.
Mio Y, Shim YH, Richards E, Bosnjak ZJ, Pagel PS, Bienengraeber M: Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats. Anesth Analg. 2009, 108: 858-866. 10.1213/ane.0b013e318192a520.PubMedCentralPubMedCrossRef
21.
Cattano D, Valleggi S, Ma D, Kastsiuchenka O, Abramo A, Sun P, Cavazzana AO, Natale G, Maze M, Giunta F: Xenon induces transcription of ADNP in neonatal rat brain. Neurosci Lett. 2008, 440: 217-221. 10.1016/j.neulet.2008.05.086.PubMedCrossRef
22.
Bantel C, Maze M, Trapp S: Neuronal preconditioning by inhalational anesthetics: evidence for the role of plasmalemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2009, 110: 986-995. 10.1097/ALN.0b013e31819dadc7.PubMedCentralPubMedCrossRef
23.
Vizcaychipi MP, Lloyd DG, Wan Y, Palazzo MG, Maze M, Ma D: Xenon pretreatment may prevent early memory decline after isoflurane anesthesia and surgery in mice. PLoS One. 2011, 6: e26394-10.1371/journal.pone.0026394.PubMedCentralPubMedCrossRef
24.
Limatola V, Ward P, Cattano D, Gu J, Giunta F, Maze M, Ma D: Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion. Neuroscience. 2010, 165: 874-881. 10.1016/j.neuroscience.2009.10.063.PubMedCrossRef
25.
Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, Hossain M, Maxwell PH, Maze M: Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol. 2009, 20: 713-720. 10.1681/ASN.2008070712.PubMedCentralPubMedCrossRef
26.
Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med (Maywood). 2010, 235: 886-891. 10.1258/ebm.2010.009366.CrossRef
27.
Weber NC, Kandler J, Schlack W, Grueber Y, Frädorf J, Preckel B: Intermitted pharmacologic pretreatment by xenon, isoflurane, nitrous oxide, and the opioid morphine prevents tumor necrosis factor alpha-induced adhesion molecule expression in human umbilical vein endothelial cells. Anesthesiology. 2008, 108: 199-207. 10.1097/01.anes.0000299441.32091.ed.PubMedCrossRef
28.
Pagel PS, Krolikowski JG, Shim YH, Venkatapuram S, Kersten JR, Weihrauch D, Warltier DC, Pratt PF: Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. Anesth Analg. 2007, 105: 562-569. 10.1213/01.ane.0000278083.31991.36.PubMedCrossRef
29.
Pagel PS, Krolikowski JG, Pratt PF, Shim YH, Amour J, Warltier DC, Weihrauch D: The mechanism of helium-induced preconditioning: a direct role for nitric oxide in rabbits. Anesth Analg. 2008, 107: 762-768. 10.1213/ane.0b013e3181815995.PubMedCentralPubMedCrossRef
30.
Baumert JH, Hein M, Gerets C, Baltus T, Hecker KE, Rossaint R: The effect of xenon anesthesia on the size of experimental myocardial infarction. Anesth Analg. 2007, 105: 1200-1206. 10.1213/01.ane.0000284697.73471.9c.PubMedCrossRef
31.
Valleggi S, Cavazzana AO, Bernardi R, Ma D, Natale G, Maze M, Cattano D, Giunta F: Xenon up-regulates several genes that are not up-regulated by nitrous oxide. J Neurosurg Anesthesiol. 2008, 20: 226-232. 10.1097/ANA.0b013e31817da878.PubMedCrossRef
32.
Weber NC, Frässdorf J, Ratajczak C, Grueber Y, Schlack W, Hollmann MW, Preckel B: Xenon induces late cardiac preconditioning in vivo: a role for cyclooxygenase 2?. Anesth Analg. 2008, 107: 1807-1813. 10.1213/ane.Ob013e31818874bf.PubMedCrossRef
33.
Luo Y, Ma D, Ieong E, Sanders RD, Yu B, Hossain M, Maze M: Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology. 2008, 109: 782-789. 10.1097/ALN.0b013e3181895f88.PubMedCrossRef
34.
Ma D, Hossain M, Pettet GK, Luo Y, Lim T, Akimov S, Sanders RD, Franks NP, Maze M: Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab. 2006, 26: 199-208. 10.1038/sj.jcbfm.9600184.PubMedCrossRef
35.
Baumert JH, Hein M, Gerets C, Baltus T, Hecker KE, Rossaint R: The effect of xenon on isoflurane protection against experimental myocardial infarction. J Cardiothorac Vasc Anesth. 2009, 23: 614-618. 10.1053/j.jvca.2009.01.028.PubMedCrossRef
36.
Shu Y, Patel SM, Pac-Soo C, Fidalgo AR, Wan Y, Maze M, Ma D: Xenon pretreatment attenuates anesthetic-induced apoptosis in the developing brain in comparison with nitrous oxide and hypoxia. Anesthesiology. 2010, 113: 360-368. 10.1097/ALN.0b013e3181d960d7.PubMedCrossRef
37.
Chakkarapani E, Thoresen M, Hobbs CE, Aquilina K, Liu X, Dingley J: A closed-circuit neonatal xenon delivery system: a technical and practical neuroprotection feasibility study in newborn pigs. Anesth Analg. 2009, 109: 451-460. 10.1213/ane.0b013e3181aa9550.PubMedCrossRef
Metadata
Title
Xenon preconditioning: molecular mechanisms and biological effects
Authors
Wenwu Liu
Ying Liu
Han Chen
Kan Liu
Hengyi Tao
Xuejun Sun
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Medical Gas Research / Issue 1/2013
Electronic ISSN: 2045-9912
DOI
https://doi.org/10.1186/2045-9912-3-3

Other articles of this Issue 1/2013

Medical Gas Research 1/2013 Go to the issue

Review

The immunomodulatory role of carbon monoxide during transplantation

Review

The role of helium gas in medicine

Review

Normobaric hyperoxia-based neuroprotective therapies in ischemic stroke

Research

Serum leptin levels decrease after permanent MCAo in the rat and remain unaffected by delayed hyperbaric oxygen therapy

Study protocol

Does hyperbaric oxygen therapy have the potential to improve salivary gland function in irradiated head and neck cancer patients?

Editorial

Quoth the Raven: carbon monoxide and nothing more
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits